DE60210329D1 - Kombinierte tumortherapie auf der basis von substituierten acryloyl-distamycin-derivaten und protein-kinase (serin/threonin-kinase) inhibitoren - Google Patents

Kombinierte tumortherapie auf der basis von substituierten acryloyl-distamycin-derivaten und protein-kinase (serin/threonin-kinase) inhibitoren

Info

Publication number
DE60210329D1
DE60210329D1 DE60210329T DE60210329T DE60210329D1 DE 60210329 D1 DE60210329 D1 DE 60210329D1 DE 60210329 T DE60210329 T DE 60210329T DE 60210329 T DE60210329 T DE 60210329T DE 60210329 D1 DE60210329 D1 DE 60210329D1
Authority
DE
Germany
Prior art keywords
kinase
threonine
serin
inhibitors
distamycin derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60210329T
Other languages
English (en)
Other versions
DE60210329T2 (de
Inventor
Cristina Geroni
Camilla Fowst
Paolo Cozzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nerviano Medical Sciences SRL
Original Assignee
Nerviano Medical Sciences SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences SRL filed Critical Nerviano Medical Sciences SRL
Publication of DE60210329D1 publication Critical patent/DE60210329D1/de
Application granted granted Critical
Publication of DE60210329T2 publication Critical patent/DE60210329T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE60210329T 2002-01-02 2002-12-18 Kombinierte tumortherapie auf der basis von substituierten acryloyl-distamycin-derivaten und protein-kinase (serin/threonin-kinase) inhibitoren Expired - Lifetime DE60210329T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02075052 2002-01-02
EP02075052 2002-01-02
PCT/EP2002/013092 WO2003055522A1 (en) 2002-01-02 2002-12-18 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors

Publications (2)

Publication Number Publication Date
DE60210329D1 true DE60210329D1 (de) 2006-05-18
DE60210329T2 DE60210329T2 (de) 2006-11-30

Family

ID=8185508

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60210329T Expired - Lifetime DE60210329T2 (de) 2002-01-02 2002-12-18 Kombinierte tumortherapie auf der basis von substituierten acryloyl-distamycin-derivaten und protein-kinase (serin/threonin-kinase) inhibitoren

Country Status (24)

Country Link
US (1) US20060084612A1 (de)
EP (1) EP1461083B1 (de)
JP (1) JP2005516025A (de)
KR (1) KR20040078118A (de)
CN (1) CN1617744A (de)
AT (1) ATE321572T1 (de)
AU (1) AU2002352090B8 (de)
BR (1) BR0215454A (de)
CA (1) CA2472008C (de)
CY (1) CY1105269T1 (de)
DE (1) DE60210329T2 (de)
DK (1) DK1461083T3 (de)
ES (1) ES2263835T3 (de)
HU (1) HUP0402639A3 (de)
IL (2) IL162820A0 (de)
MX (1) MXPA04006543A (de)
NO (1) NO20043217L (de)
NZ (1) NZ533854A (de)
PL (1) PL371179A1 (de)
PT (1) PT1461083E (de)
RU (1) RU2328306C2 (de)
SI (1) SI1461083T1 (de)
WO (1) WO2003055522A1 (de)
ZA (1) ZA200405290B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130016413A (ko) * 2002-07-30 2013-02-14 아에테르나 젠타리스 게엠베하 항종양 약제와 조합하여 사용하기 위한 알킬포스포콜린의 약물 제품
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
AU2006233856A1 (en) * 2005-04-08 2006-10-19 Nerviano Medical Sciences S.R.L. Antitumor combination comprising substituted acryloyl distamycin derivatives and antibodies inhibiting growth factors or their receptors
WO2011123691A1 (en) 2010-03-31 2011-10-06 Keryx Biopharmaceuticals, Inc. Perifosine and capecitabine as a combined treatment for cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274576B1 (en) * 1995-06-27 2001-08-14 The Henry Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
GB9615692D0 (en) * 1996-07-25 1996-09-04 Pharmacia Spa Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
GB0015447D0 (en) * 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl derivates and alkylating agents
GB0015444D0 (en) * 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors

Also Published As

Publication number Publication date
KR20040078118A (ko) 2004-09-08
HUP0402639A2 (hu) 2005-04-28
CA2472008C (en) 2009-07-28
HUP0402639A3 (en) 2012-02-28
EP1461083B1 (de) 2006-03-29
NZ533854A (en) 2007-05-31
MXPA04006543A (es) 2004-10-04
US20060084612A1 (en) 2006-04-20
CN1617744A (zh) 2005-05-18
WO2003055522A1 (en) 2003-07-10
JP2005516025A (ja) 2005-06-02
SI1461083T1 (sl) 2006-08-31
AU2002352090B2 (en) 2008-05-15
DK1461083T3 (da) 2006-07-10
CY1105269T1 (el) 2010-03-03
PT1461083E (pt) 2006-08-31
AU2002352090A1 (en) 2003-07-15
IL162820A (en) 2010-04-15
ES2263835T3 (es) 2006-12-16
EP1461083A1 (de) 2004-09-29
RU2328306C2 (ru) 2008-07-10
PL371179A1 (en) 2005-06-13
NO20043217L (no) 2004-07-30
DE60210329T2 (de) 2006-11-30
CA2472008A1 (en) 2003-07-10
RU2004123641A (ru) 2005-06-10
AU2002352090B8 (en) 2008-06-19
ATE321572T1 (de) 2006-04-15
ZA200405290B (en) 2005-06-17
BR0215454A (pt) 2004-11-23
IL162820A0 (en) 2005-11-20

Similar Documents

Publication Publication Date Title
EA200701302A1 (ru) 4-(n-фениламино)хиназолины/-хинолины в качестве ингибиторов тирозинкиназы
ATE297394T1 (de) Jun kinase inhibitoren
NO20065148L (no) Monocykliske heterocykler som kinase inhibitorer
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
EA201000093A1 (ru) Производные пиридазинона
ATE512957T1 (de) Hemmer der akt aktivität
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
EA200901601A1 (ru) Производные пиридазинона
ATE343575T1 (de) Azaoxoindol derivate als trk protein kinase hemmstoffe zur behandlung von krebs und chronischem schmerz
EA200901603A1 (ru) Арил-эфирные производные пиридазинона
DE602004011924D1 (de) Chinazoline derivate und ihre anwendung in der krebsbehandlung
ATE305787T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
CY1105269T1 (el) Συνδυασμενη θepαπεια εναντι ογκων που πepιλαμβανει υποκατεστημενα παραγωγα ακρυλοϋλ δισταμυκινης και αναστολεις κινασης πρωτεϊνης (κιναση σepινης/θρεονινης)
DK1292290T3 (da) Kombineret terapi mod tumorer omfattende substitueret acryloyl distamycinderivater og topoisomerase I og II inhibitorer
ATE435200T1 (de) Guanidinophenylalanin-verbindungen als urokinase- inhibitoren
ATE415165T1 (de) Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivate und antimetabolische mitteln
DK1261325T3 (da) Tumorinhiberende sammensætninger, der indeholder nitroacridiner

Legal Events

Date Code Title Description
8364 No opposition during term of opposition